Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

4.3%

1 terminated/withdrawn out of 23 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

39%

9 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
6(30.0%)
Phase 3
6(30.0%)
Phase 1
4(20.0%)
Phase 4
3(15.0%)
Phase 2
1(5.0%)
20Total
N/A(6)
Phase 3(6)
Phase 1(4)
Phase 4(3)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (23)

Showing 20 of 23 trials
NCT07289880Not ApplicableNot Yet Recruiting

Efficacy of Diacylglycerol Oil on Metabolic Risk Factors in Prediabetes

Role: lead

NCT07153744Phase 4Not Yet Recruiting

Efficacy and Safety of Shexiang Baoxin Pill(MUSKARDIA) in the Treatment of Acute Myocardial Infarction

Role: collaborator

NCT05439135Not ApplicableRecruiting

Washed Microbiota Transplantation for Malnutrition After Nonphysiological Reconstruction of the Upper Gastrointestinal Tract

Role: collaborator

NCT03700801Phase 4Completed

Study of Efficacy, Weight Control, and Safety in Newly-diagnosed Type 2 Diabetes With Different Antidiabetic Therapy

Role: collaborator

NCT03082924Not ApplicableCompleted

Surface EMGdi Evaluate the Efficacy of Pulmonary Rehabilitation in Patients With COPD: a Multi Center Prospective Study

Role: collaborator

NCT06012318Unknown

Dynamic Follow-up of Symptoms Based on Patient-reported Outcomes in Immunotherapy for Esophageal Cancer: a Prospective Multicentre Cohort Study (SPRING)

Role: collaborator

NCT05253222Not ApplicableUnknown

Methodology and Clinical Value of RIT in Intestinal Obstructive Diseases Mediated by Colonic TET

Role: collaborator

NCT04041349Phase 4Unknown

Clinical Observation for the Therapeutic Effect of mNGF on Cognitive Decline in Cerebral Small Vessel Disease

Role: collaborator

NCT02958111Phase 3Unknown

Single-agent Capecitabine as Adjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

Role: collaborator

NCT02736552Phase 3Withdrawn

Compare S-1 for 6 Months to 1 Year as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer Staged II , IIIA or IIIB.

Role: collaborator

NCT02745509Not ApplicableCompleted

Extensive Intraoperative Peritoneal Lavage After Curative Gastrectomy for Locally Advanced Gastric Cancer (SEIPLUS)

Role: collaborator

NCT03725800Unknown

Long-term MOno-Antiplatelet Drug Strategy After PerCutanEous CoronAry InterveNtion

Role: collaborator

NCT03706326Phase 1Unknown

CAR T and PD-1 Knockout Engineered T Cells for Esophageal Cancer

Role: lead

NCT03525782Phase 1Unknown

Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC

Role: lead

NCT03525652Phase 1Unknown

Therapeutic Vaccine Plus PD-1 Knockout in Prostate Cancer Treatment

Role: lead

NCT03503136Phase 3Not Yet Recruiting

Nedaplatin Versus Cisplatin and Capecitabine Versus Fluorouracil in IC + CCRT for Locoregionally Advanced NPC

Role: collaborator

NCT03375580Not ApplicableUnknown

Therapeutic Effects of Compound Zhenzhu Tiaozhi Capsules in NAFLD

Role: lead

NCT03191773Phase 1Unknown

A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies

Role: collaborator

NCT01540136Phase 3Completed

Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Nasopharyngeal Carcinoma

Role: collaborator

NCT02934906Unknown

Study on the Anti-HPA Antibodies Caused Neonatal Alloimmune Thrombocytopenia in Chinese Pregnant Women

Role: collaborator